By Counterforce Health Team in Enhertu (fam-trastuzumab deruxtecan-nxki) —

How Long Does It Take to Get Enhertu Approved by UnitedHealthcare in New York? Timeline & Milestones

Answer Box: Enhertu Approval Timeline with UnitedHealthcare in New York

Standard timeline: 5-15 business days for non-urgent requests, 24-72 hours for expedited oncology cases. Fastest path: Submit complete PA through UHC Provider Portal with HER2 biomarker results, prior therapy documentation, and oncologist attestation. Start today: Have your oncologist verify Enhertu is on your plan's PA list and gather pathology reports showing HER2 status. New York residents have strong appeal rights through DFS external review if denied.

Table of Contents

  1. What Affects Enhertu Approval Timing
  2. Pre-Submission Preparation (0-2 Days)
  3. Submission to Initial Review (1-5 Days)
  4. Additional Information Requests (1-7 Days)
  5. Decision Window & Outcomes
  6. If Denied: Appeal Timeline
  7. Renewal Cycles & Reauthorization
  8. Timeline Visual & Milestones
  9. Time-Saving Tips for Faster Approval

What Affects Enhertu Approval Timing

Several factors determine how quickly UnitedHealthcare processes your Enhertu (fam-trastuzumab deruxtecan-nxki) prior authorization in New York:

Benefit Type & Plan Structure

  • Medical benefit coverage: Most IV oncology drugs like Enhertu are covered under your medical benefit, processed by UHC's medical management team
  • OptumRx involvement: Some plans route specialty oncology drugs through OptumRx, UnitedHealthcare's pharmacy benefit manager
  • Plan type matters: Medicare Advantage plans must follow CMS timelines (72 hours standard, 24 hours expedited), while commercial plans follow state regulations

Complexity of Coverage Criteria

Enhertu requires extensive documentation due to its high cost (~$150,000 annually) and specific FDA indications:

  • HER2 biomarker requirements: Must provide pathology reports with IHC/ISH results
  • Line of therapy documentation: Prior HER2-directed treatments and outcomes
  • ILD risk mitigation: Baseline pulmonary assessment and monitoring plan

Completeness of Initial Submission

The biggest factor affecting timeline is whether your oncologist submits a complete PA request initially. Missing documentation triggers back-and-forth requests that can add 5-10 days.

Pre-Submission Preparation (0-2 Days)

Essential Documents Checklist

Patient Information:

  • UnitedHealthcare member ID and group number
  • Current insurance card (front and back)
  • Contact information for patient and prescribing oncologist

Clinical Documentation:

  • Pathology report with HER2 status (IHC 3+ or ISH positive for HER2-positive indications; IHC 1-2+ for HER2-low)
  • Staging scans showing metastatic or unresectable disease
  • Treatment history with dates, responses, and reasons for discontinuation
  • Performance status and key comorbidities

Prescriber Requirements:

Verify Plan Coverage

Before starting, confirm Enhertu is on your plan's prior authorization list. Call the member services number on your insurance card and ask:

  • "Is Enhertu covered under my medical benefit?"
  • "What prior authorization requirements apply?"
  • "Are there step therapy requirements for HER2-targeted drugs?"
Tip: Have your oncologist's office check the current UHC oncology PA requirements as these update regularly.

Submission to Initial Review (1-5 Days)

New York State Timeline Requirements

New York doesn't set specific timelines for private insurance PA decisions, but UnitedHealthcare has committed to industry standards:

  • Urgent oncology requests: 24-72 hours
  • Standard requests: 5-15 business days
  • Medicare plans: Must follow CMS rules (72 hours standard, 24 hours expedited)

What Reviewers Check First

UnitedHealthcare's initial review focuses on:

  1. FDA indication match: Does the diagnosis align with approved Enhertu uses?
  2. HER2 biomarker status: Documented testing with appropriate results
  3. Prior therapy requirements: Evidence of progression on or intolerance to prior HER2-directed therapy
  4. Prescriber credentials: Board-certified oncologist
  5. Safety considerations: ILD risk assessment and monitoring plan

Electronic vs. Manual Processing

OptumRx PreCheck Prior Authorization can approve eligible requests in under 30 seconds when integrated with your clinic's EHR. However, Enhertu is not currently included in this automated system, so expect manual review.

Additional Information Requests (1-7 Days)

If UnitedHealthcare needs more information, they'll contact your oncologist's office directly. Common requests include:

Missing Documentation

  • Complete pathology report if only summary provided
  • Detailed treatment history with specific dates and outcomes
  • Current imaging showing disease status
  • Baseline pulmonary function if ILD risk factors present

How to Respond Quickly

  • Portal uploads: Use the UHC Provider Portal for fastest document submission
  • Fax backup: Keep fax confirmations as proof of delivery
  • Phone follow-up: Have clinic staff call to confirm receipt within 24 hours
Note: Each additional information request typically adds 3-5 business days to the overall timeline.

Decision Window & Outcomes

Typical Approval Patterns

Approved: Most complete Enhertu requests for FDA-approved indications are approved when proper documentation is provided. You'll receive:

  • Written approval notice with authorization number
  • Coverage effective dates (usually immediate for urgent cases)
  • Any quantity limits or site-of-care restrictions

Denied: Common denial reasons and next steps:

  • Missing biomarker data: Resubmit with complete HER2 testing
  • Step therapy not met: Document failure/intolerance of preferred alternatives
  • Off-label use: Provide guideline support (NCCN, etc.)

Reading Your Approval Letter

Look for key details:

  • Authorization number for billing
  • Approved duration (typically 6-12 months for oncology drugs)
  • Quantity limits per cycle
  • Site of care requirements (hospital outpatient vs. physician office)

If Denied: Appeal Timeline

New York provides robust appeal rights with specific timelines:

Internal Appeals with UnitedHealthcare

  • Timeline: 180 days from denial date to file
  • Decision: Typically 15-30 days for standard appeals, 72 hours for urgent
  • How to file: Through UHC Provider Portal or written request

New York External Appeal Process

If UnitedHealthcare upholds the denial, New York residents can file an external appeal through the Department of Financial Services (DFS):

Timeline:

  • 4 months to file after final internal denial
  • 30 days for standard external review decision
  • 72 hours for expedited review (24 hours for urgent drug denials)

Cost: $25 fee (waived for Medicaid or financial hardship)

Success rates: While DFS doesn't publish Enhertu-specific data, external appeals with strong oncologist support and guideline backing have substantial success rates.

Critical: Don't miss the 4-month deadline for external appeal rights in New York.

Renewal Cycles & Reauthorization

When to Reauthorize

Most Enhertu approvals require renewal every 6-12 months. Start the reauthorization process 30 days before expiration to avoid treatment gaps.

What Speeds Renewals

  • Stable disease or response: Document current imaging and tumor markers
  • Good tolerance: Note any adverse events and management
  • Continued medical necessity: Show ongoing benefit and lack of suitable alternatives

UnitedHealthcare has been reducing reauthorization requirements for some oncology drugs, though Enhertu still typically requires renewal due to its cost and monitoring needs.

Timeline Milestones

Milestone Timeline Key Actions
Pre-submission prep 1-2 days Gather documents, verify coverage
PA submission Same day Electronic portal submission preferred
Initial review 1-5 days UHC reviews for completeness
Additional info request 1-7 days Respond within 24-48 hours
Final decision 3-15 days total Approval notice or denial letter
Internal appeal 15-30 days If denied, file within 180 days
External appeal (NY) 30-72 hours DFS independent review

Expedited Timeline for Urgent Cases

For patients with rapidly progressing cancer, request expedited review:

  • Submission to decision: 24-72 hours
  • Appeal decision: 72 hours (24 hours for drug denials)
  • External review: 24-72 hours in New York

Time-Saving Tips for Faster Approval

Before Submission

  1. Use the provider portal: Electronic submissions process faster than fax
  2. Bundle all documents: Include everything in the initial request
  3. Mark as urgent: When medically appropriate for metastatic disease
  4. Verify current criteria: Check latest UHC policy updates

During Review

  1. Track status actively: Check portal daily for updates
  2. Respond immediately: To any additional information requests
  3. Maintain contact: Have clinic staff available for peer-to-peer calls
  4. Document everything: Keep records of all communications

For Appeals

  1. File quickly: Don't wait until the deadline
  2. Get specialist support: Oncologist attestation is crucial
  3. Cite guidelines: Reference NCCN, FDA label, and peer-reviewed studies
  4. Consider external review: New York's system is patient-friendly
From our advocates: We've seen cases where a complete initial submission with all required biomarker documentation and a detailed treatment history led to approval within 48 hours, while incomplete requests took 2-3 weeks due to multiple information requests. Taking time to prepare thoroughly upfront consistently saves time overall.

Counterforce Health: Streamlining Your Appeal Process

When facing complex prior authorization requirements or denials for Enhertu, Counterforce Health helps patients and clinicians turn insurance denials into targeted, evidence-backed appeals. The platform analyzes denial letters and plan policies to draft point-by-point rebuttals aligned with UnitedHealthcare's specific criteria, pulling the right clinical evidence and regulatory citations to support your case.

For Enhertu appeals, this means identifying whether the denial stems from missing HER2 biomarker data, step therapy requirements, or "not medically necessary" determinations, then crafting responses that address UnitedHealthcare's exact concerns with FDA labeling, NCCN guidelines, and peer-reviewed studies. The system tracks New York's specific appeal deadlines and procedural requirements, ensuring you don't miss critical timelines while building the strongest possible case for coverage.

Frequently Asked Questions

How long does UnitedHealthcare PA take for Enhertu in New York? Standard requests: 5-15 business days. Expedited oncology cases: 24-72 hours. Timeline depends on completeness of initial submission and plan type.

What if Enhertu is non-formulary on my plan? You can request a formulary exception by showing medical necessity and failure of covered alternatives. New York's external appeal process provides additional recourse.

Can I request an expedited appeal in New York? Yes, both UnitedHealthcare internal appeals and New York DFS external appeals offer expedited review for urgent medical situations, typically decided within 72 hours.

Does step therapy apply to Enhertu? UnitedHealthcare typically requires documentation of prior HER2-directed therapy failure or intolerance. You can request step therapy exceptions for contraindications or medical necessity.

What happens if I miss the appeal deadline? Internal appeal deadlines with UnitedHealthcare are typically 180 days. New York external appeals must be filed within 4 months of final internal denial. Missing these deadlines generally eliminates appeal rights.

How much does Enhertu cost with UnitedHealthcare coverage? With coverage, you'll pay your plan's specialty drug coinsurance (typically 20-50%). The ENHERTU4U copay program may reduce costs to $0 for eligible commercially insured patients.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical advice. Coverage decisions depend on your specific insurance plan and clinical situation. Always consult with your healthcare provider and insurance company for personalized guidance. For additional help with insurance appeals in New York, contact Community Health Advocates at 888-614-5400 or the New York State Department of Financial Services consumer helpline.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.